Skip to main content
. 2014 Jun 30;32(22):2380–2385. doi: 10.1200/JCO.2014.55.2208

Fig 3.

Fig 3.

Estimated survival curves and the hazard ratio with reconstructed data for comparing modified FOLFOX6 (mFF6) plus bevacizumab (Bev) with mFF6 in patients with stage II to III colon cancer. (A) Estimated survival curves for mFF6 + Bev (blue) and mFF6 (gold). (B) Estimate of the ratio of hazard functions (mFF6 + Bev over mFF6) and the corresponding 0.95 point-wise confidence band.